This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

daclatasvir (Daklinza®)

Reference No. 1464

Publication date:

Appraisal information

daclatasvir (Daklinza®) 30 mg film-coated tablet
daclatasvir (Daklinza®) 60 mg film-coated tablet

Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 25/02/2015
AWMSG meeting date: 25/03/2015
Submission Type: Full Submission
Status: Superseded
Advice No: 0615
Ratification by Welsh Government: 15/05/2015

Current Progress

Ratification by
Welsh Government

AWMSG advice

NICE GUIDANCE HAS BEEN WITHDRAWN BECAUSE BRISTOL-MYERS SQUIBB HAS DISCONTINUED DACLATASVIR (DAKLINZA) (NOVEMBER 2019) AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA364) NICE GUIDANCE ISSUED NOVEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Daclatasvir (Daklinza®) in combination with other medicinal products is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults. Use should be restricted to patients with significant fibrosis (METAVIR score ≥ F3) or compensated cirrhosis. Daclatasvir (Daklinza®) in combination with other medicinal products is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary